Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer

Journal for ImmunoTherapy of Cancer

Jun Yong Park¹  Hyung Soon Park²  Choong-kun Lee³  Jii Bum Lee³  Woo Sun Kwon⁴  Eunji Jo⁴  Minkyu Jung⁴  Hyun Cheol Chung⁴  Tae Soo Kim⁴  Sejung Park⁴  So Jung Lim⁴  Sun Young Rha⁴  Seung-Hoon Beom⁴  Hyo Song Kim⁴ 

[1] Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine;Division of Medical Oncology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea;Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine;Songdang Institute for Cancer Research, Yonsei University College of Medicine;

关键词: Cytokines;    Immune profile;    Body fluid;    Metastatic gastric cancer;   

DOI  :  10.1186/s40425-019-0708-8

来源: DOAJ

【 摘 要 】

Abstract Background The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or monitoring source for immune checkpoint inhibitor. Methods Body fluid including ascites and pleural fluid were obtained from 55 mGC patients and 24 matched blood. VEGF-A, IL-10, and TGF-β1 were measured and immune cells were profiled by fluorescence assisted cell sorting (FACS). Results VEGF-A and IL-10 were significantly higher in body fluid than in plasma of mGC. Proportion of T lymphocytes with CD69 or PD-1, memory T cell marked with CD45RO, and number of Foxp3+ T regulatory cells (Tregs) were significantly higher in body fluid than those in blood of mGC. Proportion of CD8 T lymphocyte with memory marker (CD45RO) and activation marker (HLA-DR), CD3 T lymphocyte with PD-1, and number of FoxP3+ Tregs were identified as independent prognostic factors. When patients were classified by molecular subgroups of primary tumor, VEGF-A was significantly higher in genomically stable (GS)-like group than that in chromosomal instability (CIN)-like group while PD-L1 positive tumor cells (%) showed opposite results. Monitoring immune dynamics using body fluid was also feasible. Early activated T cell marked with CD25 was significantly increased in chemotherapy treated group. Conclusions By analyzing cytokines and proportion of immune cells in body fluid, prognosis of patients with mGC can be predicted. Immune monitoring using body fluid may provide more effective treatment for patients with mGC.

【 授权许可】

Unknown